Goldman Sachs analysts removed Novo Nordisk (NVO) from its European Conviction List as part of its monthly update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Hims & Hers Health (HIMS) Is About to Report Q2 Earnings. Here’s What to Expect
- Trump posts letters calling on drug company CEOs to lower prices
- Novo Nordisk downgraded to Hold from Buy at HSBC
- Is Novo Nordisk Stock a Falling Knife? Here’s What This Top Investor Thinks
- Novo Nordisk price target lowered to DKK 500 from DKK 650 at JPMorgan